Novel oral anticoagulant and kidney injury: Apixaban-related acute interstitial nephritis

14Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Non-vitamin K oral anticoagulants (NOACs) are being increasingly prescribed. These drugs act rapidly, have predictable dose-related anticoagulation effect and require no routine laboratory monitoring, making them attractive for both patients and healthcare providers. All NOACs are at least partially excreted thought the kidneys. Renal injury related to NOAC use is being increasingly reported. NOAC-related acute interstitial nephritis (AIN) has only been reported once and that was in context of dabigatran use. We describe the first case of apixaban-related AIN. This case adds an important differential diagnoses that should be considered for any patient presenting with renal injury while being treated with NOACs.

Cite

CITATION STYLE

APA

Abdulhadi, B., Mulki, R., Goyal, A., & Rangaswami, J. (2017). Novel oral anticoagulant and kidney injury: Apixaban-related acute interstitial nephritis. BMJ Case Reports, 2017. https://doi.org/10.1136/bcr-2017-221641

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free